Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease

Neurology

Volumn 84, Issue 16, 2015, Pages 1669-1672

  Calandrella, Daniela ^a   Romito, Luigi M ^a,b   Elia, Antonio E ^a,b   Del Sorbo, Francesca ^a,b   Bagella, Caterina F ^a,b   Falsitta, Massimo ^c   Albanese, Alberto ^a,b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG IMPLANT; DRUG IMPLANTATION; DRUG WITHDRAWAL; DUODENAL LEVODOPA INFUSION; DUODENUM PERFORATION; DYSKINESIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INFECTION; JEJUNUM ULCER; MALE; MONOTHERAPY; MOTOR CONTROL; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PERITONITIS; PHYTOBEZOAR; PRIORITY JOURNAL; ADVERSE EFFECTS; AGED; DUODENUM; INFUSION; INFUSION PUMP; MIDDLE AGED; SURGERY;

AGED; ANTIPARKINSON AGENTS; DUODENUM; FEMALE; HUMANS; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, PARENTERAL; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84928128279     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001500     Document Type: Article

References (9)

1. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-265.
2. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012;19:1079-1085.
3. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013;20:5-15.
4. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-149.
5. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD). Mov Disord 1999;14:572-584.
6. Romito LM, ContarinoMF, Vanacore N, Bentivoglio AR, Scerrati M, Albanese A. Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. Mov Disord 2009;24:555-561.
7. Jost WH. Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opin Drug Saf 2014;13:447-458.
8. Syed N, Murphy J, Zimmerman T, Mark MH, Sage JI. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998;13:336-338.
9. Volkmann J, Albanese A, Antonini A, et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol 2013;260: 2701-2714.